Product Description
Mechanisms of Action: GPx Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Egypt | Japan
Approved Indications: None
Known Adverse Events: None
Company: Chugai
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Bone Diseases, Metabolic|Osteoporosis|Arthritis, Rheumatoid|Osteoarthritis|Osteoporosis, Postmenopausal
Phase 3: Osteoporosis
Phase 1: Healthy Volunteers|Osteoporosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ELEGANT | P4 |
Not yet recruiting |
Arthritis, Rheumatoid|Bone Diseases, Metabolic|Osteoarthritis|Osteoporosis |
2025-12-01 |
|
EFFECT | P4 |
Recruiting |
Bone Diseases, Metabolic|Osteoporosis, Postmenopausal |
2025-06-01 |
|
ChiCTR2300070456 | N/A |
Not yet recruiting |
Osteoporosis |
2025-04-01 |
|
EDR2201CN | N/A |
Not yet recruiting |
Osteoporosis, Postmenopausal |
2025-01-31 |